Lexaria Bioscience Corp sees significant pre-market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 Dec 25
Source: EFFECT
Lexaria Bioscience Corp is experiencing a notable pre-market price increase of 15.95%, as the stock crosses above its 5-day SMA. This movement occurs amid a slight uptick in the broader market, with the Nasdaq-100 up 0.12% and the S&P 500 up 0.08%.
The stock's rise is attributed to broad market strength, as indicated by the positive performance of major indices. Investors appear to be responding favorably to the overall market conditions, which may be contributing to the upward momentum in Lexaria's stock price.
This increase in stock price could reflect growing investor confidence in Lexaria Bioscience Corp, potentially setting the stage for further gains if the positive market trend continues.
Analyst Views on LEXX
Wall Street analysts forecast LEXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.764
Low
1.50
Averages
1.50
High
1.50
Current: 0.764
Low
1.50
Averages
1.50
High
1.50
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
